Cantor Fitzgerald Keeps Their Buy Rating on Halozyme (HALO)

In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Halozyme (HALOResearch Report), with a price target of $27.00. The company’s shares closed last Monday at $19.15, close to its 52-week high of $19.39.

According to TipRanks.com, Duncan is a 5-star analyst with an average return of 10.1% and a 51.1% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Stealth Biotherapeutics.

Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.

See today’s analyst top recommended stocks >>

Based on Halozyme’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $25.02 million. In comparison, last year the company had a GAAP net loss of $27.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Global Yacht Services, Inc. is a therapeutic company engaged in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology and oncology markets. Operations have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. Global Yacht Servicesis located in San Diego, CA.